Delivery Order SPE2DB20D2104-SPE2DB25FMXMK
- Not listed
- The Defense Logistics Agency awarded a $34,787.81 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 25, 2025. The contract is performed from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $65,345.95 to AmerisourceBergen Drug Corp for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. The contract, awarded on August 28, 2025, with an ultimate completion date of August 29, 2025, utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order valued at $18,577.92, with an ultimate completion date of August 15, 2025. The contract is non-set-aside and represents a competitive award under the federal procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $53,908.10 to AmerisourceBergen Drug Corp for Biktarvy 50-200-25 mg tablets (30-count units) on August 6, 2025, with an ultimate completion date of August 7, 2025. This firm fixed-price delivery order represents a non-set-aside, competitively awarded contract for pharmaceutical supply to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $10,426.99 to AmerisourceBergen Drug Corp for Biktarvy 50-200-25 mg tablets (30-count units) on August 4, 2025, with completion scheduled for August 5, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a single transaction under AmerisourceBergen's broader pharmaceutical supply agreements. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with a ceiling value of $55,124.14 and an ultimate completion date of August 29, 2025. The contract involves no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This firm fixed-price delivery order, valued at $66,709.27, was competitively awarded with no set-aside designation and is scheduled for completion by August 19, 2025. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Biktarvy 50-200-25 mg tablets (30-count units) with a ceiling value of $36,293.07. This firm fixed-price delivery order, with an ultimate completion date of August 22, 2025, represents a competitively awarded contract with no set-aside designation. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 13, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This contract, valued at $11,831.54, represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award based on open competition. The order is scheduled for ultimate completion by June 16, 2025, with performance taking place at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $5,898.82 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procurement procedures. The contract was awarded to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, which serves as the place of performance, with an ultimate completion date of...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMXMKDelivery Order
The Defense Logistics Agency awarded a $6,378.11 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Biktarvy 50-200-25 mg tablets in quantities of 30 units. This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded pharmaceutical procurement. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, with an ultimate completion date of August 12, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle supports military healthcare programs globally by enabling the supply of a comprehensive range of pharmaceutical products, medical supplies, vaccines, and specialty medications across multiple therapeutic domains. AmerisourceBergen's continued receipt of delivery orders through this IDC demonstrates its capability to meet federal procurement requirements and its role as a critical pharmaceutical distributor for Defense Health Agency and military healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.4k | 8/11/25 |